Master of Medicine

Fordham University Gabelli School of Business Global Healthcare Innovation Management Center to Host – AI and Healthcare: Beyond the Hype

Retrieved on: 
Wednesday, January 24, 2024
Pathology, Drink, Digital health, School, Statistics, Therapy, Health, Business school, Intelligence, AI, Wake Forest University, Drug discovery, Food, Gabelli School of Business, Hasso Plattner Institute, Master of Medicine, WFU, Management

The ultimate indicator of how successful AI will be in a healthcare setting hinges on synergizing technological innovation with institutional readiness that will ensure AI’s deployment in healthcare is both effective and transformative.

Key Points: 
  • The ultimate indicator of how successful AI will be in a healthcare setting hinges on synergizing technological innovation with institutional readiness that will ensure AI’s deployment in healthcare is both effective and transformative.
  • The Fordham University Gabelli School of Business Global Healthcare Innovation Management Center (GHIMC) has invited thought leaders and innovators from academia, as well as those working in AI and the healthcare/pharmaceutical industries to examine the depth and complexity of the issues facing researchers, entrepreneurs, and executives at this critical juncture in the development of AI.
  • This in-person event will take place on February 1, 2024, 9:00am – 3:20pm on the 12th Floor of the Lowenstein Building, 113 W. 60 Street at Fordham University’s Lincoln Center campus.
  • The panels will be moderated by Falguni Sen, Ph.D., director of the Global Healthcare Innovation Management Center, and professor of Strategy and Statistics, Gabelli School of Business; and Navid Asgari, Ph.D., associate professor of Strategy and Statistics, Gabelli School of Business.

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Retrieved on: 
Tuesday, December 5, 2023
CBR, Master of Medicine, Hollywood Private Hospital, ESR1, Metabolism, Breast cancer, FDA, Ribociclib, Incidence, SAN, Disclosure, Partial, Mutation, Curtin University, Toxicity, CDK, Webcast, Patient, Safety, Pharmaceutical industry

However, on December 5, 2023, the 2023 San Antonio Breast Cancer Symposium (SABCS) published the posters ahead of schedule.

Key Points: 
  • However, on December 5, 2023, the 2023 San Antonio Breast Cancer Symposium (SABCS) published the posters ahead of schedule.
  • “OPERA-01, our Phase 3 monotherapy pivotal trial of palazestrant, has initiated, with multiple trial sites now activated and patient dosing started.
  • Palazestrant did not affect ribociclib drug exposure in patients, and ribociclib had no clinically meaningful effect on palazestrant drug exposure.
  • There was no observed drug-drug interaction between palazestrant and palbociclib, and there was no induced metabolism or increase in exposure of either palbociclib or palazestrant when administered in combination.

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Medical Devices, Health, Clinical Trials, Medical Supplies, Sale, Aortoiliac occlusive disease, DCB, Cell, Sundance, ISET, Master of Medicine, Freedom, Restenosis, Safety, PHD, Ambient occlusion, PP, MS, Pharmaceutical industry, MBBS, Anesthetic, FRACS

The session will be held on Wednesday, November 15th, at the 50th annual VEITH Symposium in New York, New York.

Key Points: 
  • The session will be held on Wednesday, November 15th, at the 50th annual VEITH Symposium in New York, New York.
  • Professor Varcoe previously presented SWING Trial 12-month data on January 18th at the 35th Annual International Symposium on Endovascular Therapy (ISET) conference.
  • Sirolimus, a potent anti-inflammatory and anti-proliferative compound, has been used successfully in coronary drug-eluting stents.
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th

Retrieved on: 
Wednesday, September 6, 2023
Medical genetics, FRCP, University, Royal Free Hospital, University of the Witwatersrand, BioMarin Pharmaceutical, Consultant, Keck School of Medicine of USC, Achondroplasia, Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, University of Southern California, BMRN, Division, University of Minnesota Medical School, SAN, NHS foundation trust, Evelina London Children's Hospital, Hospital, Haemophilia, Master of Medicine, Hemostasis, Broadcasting, Instrumentation, Pediatrics, Bachelor of Medicine, Bachelor of Surgery, Endocrinology

SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023. BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.

Key Points: 
  • R&D Day to be Webcast Beginning at 8:00 a.m. Eastern Time September 12th
    SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m.
  • ET on Tuesday, September 12, 2023.
  • BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.
  • An archived version of the remarks will also be available through the Company's website for a limited time following the event.

Sarah Cannon Research Institute to Present Latest Oncology Research Insights at 2023 ASCO® Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Science, Health, Oncology, Research, Head, Lead, FACOG, DO, HealthOne, Colorectal cancer, Spacecraft, Sarah Cannon Research Institute, Otorhinolaryngology, Coronation of the British monarch, Atezolizumab, McKesson Corporation, Cancer, Sunitinib, Breast, MS, Adjuvant, Carcinoma, Randomness, Conjugation, Phase, Combination, Abstract, Metastasis, SCRI, HR, Kidney, MPH, Doctor of Pharmacy, Highlight, Lung, ASCO, Potent, American Society of Clinical Oncology, Physician, FRA, Annual general meeting, FACS, Thomas Jefferson National Accelerator Facility, CDT, Society, Sodium-dependent phosphate transport protein 2B, Nursing, Pharmaceutical industry, Music, Medical imaging, Safety, E450, MD, Pharmacokinetics, Pembrolizumab, Master of Medicine, Efficacy, Patient

Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.

Key Points: 
  • Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.
  • In 2022, SCRI joined together with US Oncology Research as one company to transform oncology research and improve care in more than 24 states across the U.S. Operating as SCRI, the unified research network has over 1,300 physicians enrolling patients to more than 1,000 trials annually.
  • “The collaborations across SCRI’s expanded network are accelerating progress and serving more patients closer to where they live,” says Howard A.
  • “We are looking forward to this year’s Annual Meeting where we will be discussing the results of trials that are advancing therapies across a variety of cancers.”
    For a comprehensive list of abstracts and presentations, click here .

IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update

Retrieved on: 
Tuesday, May 30, 2023
Bevacizumab, IGM, DR5, Immunoglobulin M, Assistant professor, MD, Patient, Colorectal cancer, Webcast, Master of Medicine, Pharmaceutical industry

MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that it will host a conference call and live webcast to provide an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, on Friday, June 2, 2023 at 7:00 p.m. ET.

Key Points: 
  • ET –
    MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that it will host a conference call and live webcast to provide an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, on Friday, June 2, 2023 at 7:00 p.m.
  • The Company will be providing a clinical data update on 3 mg/kg IGM-8444 + FOLFIRI (± bevacizumab) in median third line metastatic colorectal cancer patients from a non-randomized clinical trial cohort.
  • In this presentation, the Company will not be providing a clinical data update from its recently initiated randomized study of IGM-8444 + FOLFIRI and bevacizumab in second line colorectal cancer patients.
  • A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference

Retrieved on: 
Thursday, January 19, 2023
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, MS, CDR, SCB-125, ISET, PHD, Death, Sirolimus, Patient, Master of Medicine, International Symposium on Endovascular Therapy, PAD, SCB, Sundance, Pharmaceutical industry, FRACS, MBBS

The SWING trial is a first-in-human feasibility study of the Company’s Sundance™ SCB.

Key Points: 
  • The SWING trial is a first-in-human feasibility study of the Company’s Sundance™ SCB.
  • At ISET, SWING co-lead investigator Professor Ramon Varcoe, MBBS, MS, FRACS, PHD, MMed (ClinEpi), reinforced key findings from the SWING trial.
  • Rather than using encapsulation, the Sundance™ SCB delivers drug to target tissue via a coating of stable crystalline sirolimus with a proprietary excipient on the balloon surface, a method the Company describes as Crystalline Drug Release, or CDR.
  • When inflated, the Sundance™ SCB transfers this crystalline drug form to the vessel wall, whereupon the crystalized drug itself serves as the drug depot in a process that eliminates the need for a polymer depot.

Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18

Retrieved on: 
Monday, January 16, 2023
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, FRANZCR, Cell, MS, Auckland City Hospital, Aortoiliac occlusive disease, Safety, SCB Park Plaza, ISET, PHD, ONZM, Master of Medicine, Sale, DCB, Restenosis, International Symposium on Endovascular Therapy, Pharmaceutical industry, FRACS, Bachelor of Medicine, Bachelor of Surgery, MBBS, Anesthetic

The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida.

Key Points: 
  • The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida.
  • Professor Varcoe will also discuss the differentiated capabilities of the Surmodics crystalline drug release platform for sirolimus-coated balloons (SCBs) in connection with 12-month data from the SWING trial.
  • Professor Varcoe recently presented SWING Trial 12-month data on Nov. 16 at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium).
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.

Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium

Retrieved on: 
Thursday, November 17, 2022
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, MALE, Restenosis, Sale, Ambient occlusion, Peripheral artery disease, Cell, DCB, Freedom, PHD, PP, FRANZCR, MS, Safety, HIV disease progression rates, IVD, Disease, Master of Medicine, Annual report, ONZM, Growth, Classification, MD, Aortoiliac occlusive disease, Pharmaceutical industry, Medical imaging, FRACS, MBBS, Bachelor of Medicine, Bachelor of Surgery

The primary efficacy endpoint is the rate of late lumen loss at 6 months, as assessed by quantitative vascular angiography.

Key Points: 
  • The primary efficacy endpoint is the rate of late lumen loss at 6 months, as assessed by quantitative vascular angiography.
  • Both primary endpoints of the SWING Trial were achieved.
  • Primary safety endpoint data showed no perioperative deaths or major amputations at 30 days, and just one major re-intervention was reported among the 35 trial subjects.
  • The SWING Trial demonstrates that the Sundance Sirolimus DCB has tremendous promise and warrants evaluation in a large-scale pivotal trial.

Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16

Retrieved on: 
Friday, November 11, 2022
Medical Devices, Health, Surgery, Clinical Trials, General Health, Pharmaceutical, Aortoiliac occlusive disease, Sale, Company, Annual report, NASDAQ, Disease, Auckland City Hospital, Technology, Cell, DCB, SEC, Safety, Investor, 3rd Floor, Forward-looking statement, MS, Restenosis, Master of Medicine, FRANZCR, AMP, Growth, Amputation, PHD, ONZM, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, FRACS, Anesthetic, MBBS

The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.

Key Points: 
  • The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.
  • Professor Andrew Holden, MBChB, FRANZCR, EBIR, ONZM, Director of Northern Region Interventional Radiology Service at Auckland City Hospital in Auckland, New Zealand, is also a co-lead investigator for the SWING Trial.
  • Professor Varcoe recently presented SWING Trial 6-month data on October 11 as part of the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.
  • Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays.